Source comparison
In Vivo Tendon Model Comparison
The rat Achilles collagenase model (intratendinous injection of 0.5 mg collagenase type I in 50 µL PBS producing reproducible mid-tendon lesion) provides the standard comparator. Animals are randomised to: vehicle; TB-500 (500 µg/kg s.c.); BPC-157 (10 µg/kg s.
This comparison does not assign a generated winner or score.
- The rat Achilles collagenase model (intratendinous injection of 0.5 mg collagenase type I in 50 µL PBS producing reproducible mid-tendon lesion) provides the standard comparator. Animals are randomised to: vehicle; TB-500 (500 µg/kg s.c.); BPC-157 (10 µg/kg s.c. or i.g.); or TB-500 + BPC-157 combination. Endpoints at day 28: Bonar score (histological tendinopathy grading, 0 = normal, 3 = severe); Masson trichrome (collagen maturity, blue = mature collagen area %); polarised Sirius Red (red:green birefringence ratio); Instron tensile mechanical testing (failure load N, stiffness N/mm, Young’s modulus MPa); UTC (ultrasound tissue characterisation) — echo-type I (organised fibrillar collagen) vs echo-type III-IV (disorganised/degenerative) ratio.
- In comparative studies, TB-500 shows advantages in: UTC echo-type I restoration (organised collagen fibres returning to normal echo pattern); tenocyte density and alignment (H&E); and neovascularisation (CD31+ vessel density — TB-500’s FPR2-VEGF angiogenesis providing superior vascular research applications). BPC-157 shows advantages in: total collagen content (Sircol, hydroxyproline); tensile failure load research applications (highest absolute tensile load at day 28, potentially reflecting BPC-157’s TGF-β1-driven collagen deposition); and MMP-1 suppression (lower collagenolytic activity in repair tissue homogenate). Combination TB-500 + BPC-157 shows additive or synergistic effects across most endpoints — UTC echo-type I, Masson trichrome collagen maturity, and tensile failure load all trend higher than either peptide alone — consistent with their mechanistic complementarity (migration + proliferation + complementary anti-catabolic pathways).